But we believe the downward trend of the actual reports so far this year, and even more importantly how the Q2 forecasts had to be revised lower so rapidly as the quarter progressed, is the real story.
The reports are intended to give savvy investors and ordinary consumers alike an awareness of interest rates, forecastsand other developments that impinge on them.
Analyst reports continue to pour in, and almost all of them are glowingly positive, increasing sales forecasts for the drug and price targets for Genentech and OSI shares.